DepoMed (DEPO) Tops Q4 EPS by 14c, Offers Guidance

DepoMed (NASDAQ: DEPO) reported Q4 EPS of $0.21, $0.14 better than the analyst estimate of $0.07. Revenue for the quarter came in at $33.9 million versus $18.8 million last year.

2015 Financial Outlook

As of February 23, 2015, Depomed is providing its financial outlook for product revenue, excluding the effect from the NUCYNTA transaction, for the full year 2015:

Product sales of approximately $152 to $162 million.

Upon consummation of the NUCYNTA transaction which is expected to close in the second quarter of 2015, Depomed expects to provide 2015 guidance that will include the effect of the NUCYNTA transaction and cover product sales, operating expenses, EBITDA, non-GAAP earnings and non-GAAP EPS

For earnings history and earnings-related data on DepoMed (DEPO) click here.

You May Also Be Interested In

• Klarna Group plc (KLAR) Tops Q2 EPS by 6c, Beats on Revenue; Offers FY26 Revenue Guidance
• Fabrinet (FN) Tops Q4 EPS by 29c, Beats on Revenue; Offers Guidance
• uCloudlink Group Inc. (UCL) Misses Q2 EPS by 1c ; Offers Guidance